Press releases

* (R) = Regulatory press releases

Jan 13, 2016

(R) Cantargia is presenting at the Biotech Showcase in San Francisco
Jan 4, 2016

(R) Cantargia patent granted by the European Patent Office
Dec 1, 2015

(R) Exercise of warrants of series 2010:1
Nov 17, 2015

(R) Cantargia Interim Report for the period 1 July 2015 – 30 September 2015 available
Nov 17, 2015

(R) Cantargia presents new data and development plan, non-small cell lung cancer and pancreatic cancer have been selected as primary indications for CAN04
Oct 8, 2015

(R) Cantargia strengthens management with a Vice President Cancer Research
Oct 6, 2015

(R) Cantargia obtains an “Intention to Grant” notice from the European Patent Office covering the IL1RAP target for the treatment of solid tumors
Oct 5, 2015

(R) Cantargia: Grant of patent by The European Patent Office (EPO)
Aug 25, 2015

(R) Cantargia Interim Report for the period 1 Jan 2015 – 30 June 2015 available
Aug 11, 2015

(R) Data on Cantargia’s antibodies in leukemia models published in international scientific journal
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB